H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $20
Zevra Therapeutics Analyst Ratings
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $25
JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17
Zevra Therapeutics Price Target Announced at $17.00/Share by JMP Securities
Zevra Therapeutics Is Maintained at Buy by Maxim Group
A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $17 to $25
Roth MKM Keeps Their Buy Rating on Zevra Therapeutics (ZVRA)
William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating
Zevra Therapeutics Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $18
Zevra Therapeutics Analyst Ratings
Zevra Therapeutics Is Maintained at Buy by Canaccord Genuity
Zevra Therapeutics Analyst Ratings
CCORF Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Cuts Target Price to $22
William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Inmune Bio (INMB) and Zevra Therapeutics (ZVRA)
CCORF Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Cuts Target Price to $22
Roth MKM Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $19
William Blair Initiates Zevra Therapeutics(ZVRA.US) With Buy Rating